Semaglutide (Ozempic / Wegovy)
Clinical evidenceSemaglutide is a GLP-1 receptor agonist that slows gastric emptying and increases satiety signaling. FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Weekly dosing with dose escalation typically over 4–8 weeks. Not medical advice; consult a provider.
How Semaglutide (Ozempic / Wegovy) works
Semaglutide activates GLP-1 receptors to enhance insulin secretion, suppress appetite, and slow gastric emptying. Only use under a healthcare provider’s care; not for self-directed use.
Researched benefits
- •FDA-approved for type 2 diabetes and chronic weight management
- •Extensive Phase 3 data; STEP trials showed 15–17% body weight reduction
- •Supports glycemic control and cardiovascular outcome data in some populations
- •Weekly dosing with established titration schedule
What it is studied for
- •Type 2 diabetes management
- •Obesity and weight management when prescribed
- •Metabolic health in appropriate candidates
Reported side effects and cautions
- •Nausea, vomiting, diarrhea (usually transient during titration)
- •Risk of pancreatitis; contraindications exist
- •Requires prescription and medical supervision
- •Discuss thyroid and other warnings with provider
Dosing protocol described in the literature
- Dosage
- Per prescription
- Frequency
- Weekly
- Administration
- Subcutaneous
- Cycle
- Ongoing per provider
Metabolic & weight support
Evidence rating: Clinical evidence
Studied in human clinical trials. Some compounds in this tier are approved medicines for specific indications and require a prescription.
Other peptides
Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use Semaglutide (Ozempic / Wegovy). Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.